#SABCS24: Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly’s oral SERD reduced the risk of progression or death among patients with mutated estrogen receptor genes, but not in all comers ...